Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Inclusion Criteria

• •Stage II-III multiple myeloma or have progression after initial treatment of Stage I disease (Durie Salmon Staging). Patients with plasma cell leukemia are also included.
• •Multiple myeloma / plasma cell leukemia diagnosis confirmed by pathology reviewed at Stanford University Medical Center.
• •18 to ≤ 75 years of age
• •Karnofsky Performance Status \> 70%.
• •Corrected Carbon monoxide diffusing capacity (Dlco) \> 60%
• •Left ventricle ejection fraction (LVEF) \> 50%.
• •Alanine aminotransferase (ALT) ≤ 2 x normal
• •Aspartate aminotransferase (AST) ≤ 2 x normal
• •Total bilirubin ≤ 2 mg/dL, unless hemolysis or Gilbert's disease.
• •Estimated creatinine clearance \> 50 mL/min.
• •Identified related or unrelated Human leukocyte antigen (HLA)-identical donor or donor with one antigen/allele mismatch in (HLA-A, B, C or DRB1).
• •Signed informed consent.
• •At least 17 years of age
• •HIV-seronegative
• •Must be capable of giving signed, informed consent
• •No contraindication to the administration of filgrastim
• •Willing to have a central venous catheter placed for apheresis if peripheral veins are inadequate